AR032152A1 - Uso de una combinacion de compuestos terapeuticos organicos para la fabricacion de un medicamento, un agente terapeutico, y una composicion farmaceutica - Google Patents

Uso de una combinacion de compuestos terapeuticos organicos para la fabricacion de un medicamento, un agente terapeutico, y una composicion farmaceutica

Info

Publication number
AR032152A1
AR032152A1 ARP010101697A ARP010101697A AR032152A1 AR 032152 A1 AR032152 A1 AR 032152A1 AR P010101697 A ARP010101697 A AR P010101697A AR P010101697 A ARP010101697 A AR P010101697A AR 032152 A1 AR032152 A1 AR 032152A1
Authority
AR
Argentina
Prior art keywords
combination
hypertension
manufacture
pharmaceutical composition
therapeutic agent
Prior art date
Application number
ARP010101697A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR032152A1 publication Critical patent/AR032152A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401Proline; Derivatives thereof, e.g. captopril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El uso de una combinacion de cuando menos dos componentes terapéuticos en combinacion seleccionados a partir del grupo que consiste en: (i) un antagonista del receptor AT1, o un antagonista del receptor AT1 combinado con un diurético, o en cada caso, una sal farmacéuticamente aceptable de los mismos, (ii) un inhibidor de HMG-Co-A reductasa o una sal farmacéuticamente aceptable del mismo, y (iii) un inhibidor de ACE o una sal farmacéuticamente aceptable del mismo; caracterizado porque es para la fabricacion de un medicamento para la prevencion, demora de progreso, o tratamiento de una enfermedad o condicion seleccionada a partir del grupo que consiste en hiperlipidemia y dislipidemia, ateroesclerosis, resistencia a la insulina y síndrome X, diabetes mellitus tipo 2, obesidad, nefropatía, insuficiencia renal, hipotiroidismo, sobrevivencia posterior a infarto al miocardio, enfermedades cardíacas coronarias, hipertension en la ancianidad, hipertension dislipidérmica familiar, y remodelacion enseguida de hipertension (efecto antiproliferativo de la combinacion), todas estas enfermedades o condiciones asociadas con o sin hipertension, para la prevencion, demora de progreso o tratamiento de embolia, disfuncion eréctil, y enfermedad vascular para la fabricacion de un medicamento, un agente terapéutico, y una composicion farmacéutica.
ARP010101697A 2000-04-12 2001-04-10 Uso de una combinacion de compuestos terapeuticos organicos para la fabricacion de un medicamento, un agente terapeutico, y una composicion farmaceutica AR032152A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19674300P 2000-04-12 2000-04-12

Publications (1)

Publication Number Publication Date
AR032152A1 true AR032152A1 (es) 2003-10-29

Family

ID=22726659

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101697A AR032152A1 (es) 2000-04-12 2001-04-10 Uso de una combinacion de compuestos terapeuticos organicos para la fabricacion de un medicamento, un agente terapeutico, y una composicion farmaceutica

Country Status (20)

Country Link
US (2) US20040023840A1 (es)
EP (1) EP1326604A2 (es)
JP (1) JP2003530342A (es)
KR (1) KR20020089433A (es)
CN (2) CN1440283A (es)
AR (1) AR032152A1 (es)
AU (1) AU2001258323A1 (es)
BR (1) BR0109966A (es)
CA (1) CA2405793A1 (es)
CZ (1) CZ20023381A3 (es)
HU (1) HUP0400475A3 (es)
IL (1) IL152079A0 (es)
MX (1) MXPA02010090A (es)
NO (1) NO20024921L (es)
PE (1) PE20020229A1 (es)
PL (1) PL365696A1 (es)
RU (1) RU2298418C2 (es)
SK (1) SK14642002A3 (es)
WO (1) WO2001076573A2 (es)
ZA (1) ZA200208203B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1216038T3 (da) 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
US6242003B1 (en) * 2000-04-13 2001-06-05 Novartis Ag Organic compounds
NZ522953A (en) * 2000-06-22 2005-10-28 Novartis Ag Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate
US20060127474A1 (en) 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
WO2002085363A1 (en) * 2001-04-19 2002-10-31 Kowa Co., Ltd. Remedial agent for glomerular disease
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
MXPA04004844A (es) * 2001-11-23 2004-07-30 Solvay Pharm Gmbh Tratamiento de hipertonia durante la fase aguda de un accidente cerebrobascular.
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
KR101092279B1 (ko) * 2002-12-27 2011-12-13 다케다 야쿠힌 고교 가부시키가이샤 체중 증가 억제제
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
PL376213A1 (en) * 2003-01-16 2005-12-27 Boehringer Ingelheim International Gmbh Pharmaceutical combination for the prophylaxis or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
ES2421520T3 (es) * 2003-04-28 2013-09-03 Daiichi Sankyo Co Ltd Potenciador de la producción de adiponectina
AU2004233691B2 (en) * 2003-04-28 2007-09-20 Sankyo Company, Limited Sugar intake-ability enhancer
RS20060018A (sr) 2003-07-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati spojenih arila i heteroarila kao modulatori metabolizma u profilaksi i lečenju sa njima povezanih stanja
GB0322552D0 (en) * 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
AU2008201290B2 (en) * 2003-09-26 2010-12-09 Astrazeneca Uk Limited Therapeutic treatment
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
CN1889948A (zh) * 2003-12-16 2007-01-03 诺瓦提斯公司 他汀用于治疗代谢综合征的用途
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
JPWO2006046528A1 (ja) * 2004-10-29 2008-05-22 興和株式会社 糸球体疾患治療剤
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 a 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
US8685952B2 (en) 2006-01-31 2014-04-01 Kowa Co., Ltd. Method for the treatment of diabetes
KR101436644B1 (ko) * 2006-01-31 2014-09-01 코와 가부시키가이샤 당뇨병 치료제
FR2911279B1 (fr) * 2007-01-11 2009-03-06 Servier Lab Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
RU2393857C2 (ru) * 2008-05-12 2010-07-10 Государственное образовательное учреждение высшего профессионального образования Читинская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию Лекарственное средство, оказывающее противосудорожное и антигипоксическое действие
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
RU2505297C1 (ru) * 2012-11-21 2014-01-27 Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") Средство для медикаментозной коррекции нарушений нитроксидергической системы
HRP20171231T1 (hr) * 2013-05-13 2017-10-20 Macro Plastics, Inc. Transportni spremnik sa sigurnosnom bravom
BR102013028883A2 (pt) * 2013-11-08 2015-10-06 Hypermarcas S A forma farmacêutica oral para a prevenção de doenças vasculares, comprimido como forma farmacêutica e cápsula gelatinosa como forma farmacêutica
MD4412C1 (ro) * 2014-08-29 2016-11-30 Алёна ДУРНЯ Utilizare a acidului 4-({2-butil-5-[2-carboxi-2-(tiofen-2-ilmetil)et-1-en-1-il] -1H-imidazol-1-il}metil) benzoic pentru ameliorarea elasticităţii vasculare în profilaxia complicaţiilor de geneză hipertensivă
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
EA034975B1 (ru) * 2018-03-13 2020-04-13 Владимир Александрович Горшков-Кантакузен Способ лечения лабильной и пароксизмальной гипертензии
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981470A (en) * 1994-06-07 1999-11-09 The University Of Birmingham Uterine fibroid treatment
CZ313897A3 (cs) * 1995-04-07 1998-01-14 Novartis Ag Farmaceutické kompozice obsahující benazepril nebo benazeprilát a valsartan
JPH11508894A (ja) * 1995-06-30 1999-08-03 メルク エンド カンパニー インコーポレーテッド Ace阻害剤とaii拮抗薬を用いる腎疾患の治療方法
BR9708336A (pt) * 1996-03-29 1999-08-03 Smithkline Beecham Corp Diidrato de eprosartan e processo para sua produção e formulação
DE69731840T2 (de) * 1996-07-15 2005-08-04 Sankyo Co., Ltd. Pharmazeutische Zusammensetzungen enthaltend CS-866 und Insulinresistenz verbessernde Mittel und deren Verwendung zur Behandlung von Arteriosklerose und Xanthom

Also Published As

Publication number Publication date
BR0109966A (pt) 2003-08-05
WO2001076573A2 (en) 2001-10-18
KR20020089433A (ko) 2002-11-29
PL365696A1 (en) 2005-01-10
SK14642002A3 (sk) 2003-05-02
CZ20023381A3 (cs) 2003-02-12
PE20020229A1 (es) 2002-04-11
MXPA02010090A (es) 2003-02-12
RU2298418C2 (ru) 2007-05-10
HUP0400475A2 (hu) 2004-06-28
AU2001258323A1 (en) 2001-10-23
WO2001076573A3 (en) 2003-04-17
NO20024921L (no) 2002-11-07
CA2405793A1 (en) 2001-10-18
EP1326604A2 (en) 2003-07-16
ZA200208203B (en) 2003-11-07
CN1651087A (zh) 2005-08-10
CN1440283A (zh) 2003-09-03
JP2003530342A (ja) 2003-10-14
NO20024921D0 (no) 2002-10-11
HUP0400475A3 (en) 2006-02-28
US20070105894A1 (en) 2007-05-10
IL152079A0 (en) 2003-05-29
US20040023840A1 (en) 2004-02-05

Similar Documents

Publication Publication Date Title
AR032152A1 (es) Uso de una combinacion de compuestos terapeuticos organicos para la fabricacion de un medicamento, un agente terapeutico, y una composicion farmaceutica
AR032316A1 (es) Uso de una composicion farmaceutica para la fabricacion de medicamentos y una composicion farmaceutica
PE20242299A1 (es) Composiciones agonistas de gip/glp1
WO1995014384A1 (en) Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds
JP2019112409A (ja) 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用
AR005281A1 (es) Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. .
AR037255A1 (es) Composiciones farmaceuticas que contienen oxibutinina
DE60032749D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
AR018582A1 (es) Forma de dosificacion en tableta para administrar un antagonista de los receptores de los leucotrienos y su uso en la preparacion de medicamentos
RU2002105377A (ru) Ксенон-антагонист nmda
KR20070072502A (ko) 관절 류머티즘의 예방 및/또는 치료약
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
ES2840079T3 (es) Composición farmacéutica para el tratamiento de la esteatosis hepática no alcohólica
PE20040973A1 (es) Composiciones de anti-histaminicos, descongestivos y drogas anti-inflamatorias no esteroidales
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
Gaudilliere et al. To market, to market—2000
US20230277523A1 (en) Methods for inhibiting phosphate transport
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
ES2525931T3 (es) Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal
RU2007132971A (ru) Способы и материалы с транс-кломифеном для лечения мужского бесплодия
AR038858A1 (es) Combinacion
Hsu et al. Pharmacotherapy for obesity: past, present and future
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal